Form 4: Syndax CFO Sells Shares for Tax Obligations

Syndax Pharmaceuticals' CFO, Keith A. Goldan, sold 3,410 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Keith A. Goldan, Chief Financial Officer of Syndax Pharmaceuticals Inc (SNDX), reported a transaction involving company common stock.
• On February 9, 2026, Goldan sold 3,410 shares of Syndax common stock at a price of $21.028 per share.
• The sale was explicitly stated to cover tax withholding obligations in connection with the vesting of restricted stock units.
• This transaction was conducted under a Rule 10b5-1 pre-arranged trading plan.
• Following the reported transaction, Goldan beneficially owns 140,429 shares of Syndax common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executives managing tax liabilities from equity compensation, and not indicative of a change in company fundamentals or management's confidence.

Positives

• The transaction was a 'sell-to-cover' for tax obligations, which is a common and often neutral event for executives receiving equity compensation.
• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-planned and not a discretionary sale based on immediate market conditions or material non-public information.

Negatives

• An insider sale, even for tax purposes, reduces the executive's direct equity stake in the company.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an insider transaction.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard practice for executives receiving equity compensation, particularly restricted stock units (RSUs), across the pharmaceutical and biotechnology sectors. These sales are typically not indicative of a change in management's outlook on the company's prospects but rather a mechanism to manage tax liabilities.

Comparison to Industry Standards

• 'Sell-to-cover' transactions are a common mechanism for executives in publicly traded companies, including peers like Pfizer (PFE) or Merck (MRK), to manage tax obligations arising from equity compensation vesting.
• The use of a Rule 10b5-1 plan aligns with best practices for insider trading compliance, similar to plans adopted by executives at companies such as Amgen (AMGN) or Gilead Sciences (GILD), ensuring transactions are pre-scheduled and not based on material non-public information.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale, not a discretionary divestment.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Recommendation

The reported transaction is a routine 'sell-to-cover' by the Chief Financial Officer to satisfy tax obligations related to restricted stock unit vesting. This type of insider sale is common and generally not indicative of a change in the company's fundamental prospects or management's confidence, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Syndax Pharmaceuticals, SNDX, Keith A. Goldan, CFO, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan